Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.34 - $0.74 $2,176 - $4,736
6,400 Added 800.0%
7,200 $2,000
Q1 2024

May 15, 2024

SELL
$0.28 - $0.66 $504 - $1,188
-1,800 Reduced 69.23%
800 $0
Q4 2023

Feb 14, 2024

SELL
$0.15 - $0.4 $11,685 - $31,160
-77,900 Reduced 96.77%
2,600 $0
Q3 2023

Nov 14, 2023

SELL
$0.2 - $2.08 $7,220 - $75,088
-36,100 Reduced 30.96%
80,500 $16,000
Q2 2023

Aug 14, 2023

SELL
$2.0 - $3.2 $11,800 - $18,880
-5,900 Reduced 4.82%
116,600 $240,000
Q1 2023

May 15, 2023

BUY
$1.43 - $3.3 $128,700 - $297,000
90,000 Added 276.92%
122,500 $404,000
Q4 2022

Feb 14, 2023

BUY
$1.37 - $4.42 $21,783 - $70,278
15,900 Added 95.78%
32,500 $53,000
Q3 2022

Nov 14, 2022

SELL
$2.55 - $4.42 $7,139 - $12,376
-2,800 Reduced 14.43%
16,600 $73,000

Others Institutions Holding BCLI

About BRAINSTORM CELL THERAPEUTICS INC.


  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $44.5M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.